Sign in
CompletedPhase 4

Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)

Key facts

Who runs it
Zhang Xiaofeng,MD
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
370 people enrolled
Started
1 Nov 2023
Ended
31 Oct 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tegoprazan 50 mg, tablets, orally, qd
  • Esomeprazole 20mg BID
  • Tegoprazan 50 mg, tablets, orally, bid
  • amoxicillin +clarithromycin+colloidal bismuth pectin BID
  • amoxicillin 1000mg tid
Record updated
16 January 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients aged ≥18 years with Hp-positive first sterilization were included in this study
  • Before treatment, the existence of Helicobacter pylori can be confirmed by one or more of the following methods: rapid urease test, Hp culture, 13C urea breath test, 14C urea breath test and stool Hp antigen test

Who cannot take part

  • previous eradication treatment of Helicobacter pylori
  • surgery that may affect gastric acid secretion (upper gastrointestinal resection or vagotomy)
  • acute upper gastrointestinal bleeding
  • active gastric or duodenal ulcer
  • penicillin/furazolidone allergy
  • Zollinger-Ellison syndrome or other hypergastric acid secretion diseases
  • acute gastric or duodenal mucosal lesions
  • severe neurological, cardiovascular, pulmonary, liver,renal, metabolic,gastrointestinal, urological, etc
  • Any fertile woman must use proper contraception

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Standard eradication therapies using proton pump inhibitors (PPIs) require double doses to achieve sufficient acid suppression, yet failure rates remain high due to antibiotic resistance. Tegoprazan, a P-CAB agent, inhibits gastric acid more effectively than PPIs. This study hypothesizes that Tegoprazan-based dual therapy can achieve superior or non-inferior eradication rates compared to standard quadruple therapy. The study evaluates the antibacterial effect of Tegoprazan combined with high-dose Amoxicillin in H. pylori-infected patients.

The 3 groups in the trial

  • Tegoprazan 50mg QDTreatment being tested

    Tegoprazan 50 mg once daily plus Amoxicillin 1000mg TID for up to 2 weeks

    Treatment: Tegoprazan 50 mg, tablets, orally, qd and amoxicillin 1000mg tid

  • Esomeprazole 20 mg BIDExisting treatment, for comparison

    esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg,clarithromycin 500mg bid,colloidal bismuth pectin 200mg bid for up to 2 weeks. OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks.

    Treatment: Esomeprazole 20mg BID and amoxicillin +clarithromycin+colloidal bismuth pectin BID

  • Tegoprazan 50 mg BIDTreatment being tested

    Tegoprazan 50 mg twice daily plus Amoxicillin plus Amoxicillin 1000mg TID for up to 2 weeks

    Treatment: Tegoprazan 50 mg, tablets, orally, bid and amoxicillin 1000mg tid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tegoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Based Bismuth Quadruple Therapy for First-Line Helicobacter Pylori Eradication: A Prospective, Randomized, Multicenter, Superiority Study (TATH-1)
Record updated
16 January 2026